Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2011 1
2015 1
2016 1
2019 1
2021 1
2022 1
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
Tofacitinib for the treatment of acute severe ulcerative colitis refractory to infliximab.
Fortuny Bauzá M, Cañete Pizarro F, Calm Salvans A, Calafat Sard M, Domènech Morral E. Fortuny Bauzá M, et al. Among authors: domenech morral e. Gastroenterol Hepatol. 2022 Apr;45 Suppl 1:11-12. doi: 10.1016/j.gastrohep.2021.05.005. Epub 2021 Jun 9. Gastroenterol Hepatol. 2022. PMID: 34118322 English, Spanish. No abstract available.
The Risk of Developing Disabling Crohn's Disease: Validation of a Clinical Prediction Rule to Improve Treatment Decision Making.
Bastida Paz G, Merino Ochoa O, Aguas Peris M, Barreiro-de Acosta M, Zabana Y, Ginard Vicens D, Ceballos Santos D, Muñoz Núñez F, Monfort I Miquel D, Catalán-Serra I, García Sánchez V, Loras Alastruey C, Lucendo Villarín A, Huguet JM, de la Coba Ortiz C, Aldeguer Manté X, Palau Canós A, Domènech Morral E, Nos P; GETECCU Group (Spanish Working Group on Crohn’s Disease and Ulcerative Colitis). Bastida Paz G, et al. Among authors: domenech morral e. Dig Dis. 2023;41(6):879-889. doi: 10.1159/000531789. Epub 2023 Aug 23. Dig Dis. 2023. PMID: 37611561
Post-marketing health technology monitoring. The analysis of an experience from a clinical perspective.
Ibargoyen-Roteta N, Cabriada-Nuño JL, Gutiérrez-Ibarluzea I, Hernández-Ramírez V, Clofent-Vilaplana J, Domènech-Morral E, Ginard-Vicens D, Oliva-Oliva G, Queiro-Verdes T. Ibargoyen-Roteta N, et al. Among authors: domenech morral e. Front Pharmacol. 2011 Jul 29;2:45. doi: 10.3389/fphar.2011.00045. eCollection 2011. Front Pharmacol. 2011. PMID: 21863141 Free PMC article.
Poor correlation between acute phase reactants and intestinal involvement in patients with onset of Crohn's disease under treatment with an interleukin-6 inhibitor due to seronegative arthropathy.
Zacarías Martínez L, Mateo Soria L, Mañosa Círia M, Clos Parals A, Cabré Gelada E, Domènech Morral E. Zacarías Martínez L, et al. Among authors: domenech morral e. Gastroenterol Hepatol. 2016 Dec;39(10):670-672. doi: 10.1016/j.gastrohep.2015.10.001. Epub 2015 Nov 15. Gastroenterol Hepatol. 2016. PMID: 26589538 English, Spanish. No abstract available.